MedTrace Logo

The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial

NCT04562428 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-05-16

No results posted yet for this study

Summary

The purpose of the study was search the safety and efficacy of the of Xiang Sha Liu Jun Zi Decoction (XSLJZ) in advanced hepatocellular carcinoma patients with multiple protein kinase inhibitor therapy. Evaluate the treatment effect on the symptoms of appetite and quality of life in advanced hepatocellular carcinoma patients

Conditions

Interventions

DRUG

Xiang Sha Liu Jun Zi Decoction dry powder

the principles of Chinese medicine treatment areinvigorating Pi, regulating qi, dissipating dampness and appetizing wei

DRUG

XSLJZ Placebo

XSLJZ Placebo

Sponsors & Collaborators

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • YuanChing Liao · China Medial University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2020-12-31
Completion
2023-05-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04562428 on ClinicalTrials.gov